High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients-Reference-Cited by-同舟云学术

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients

Published:2015-06 Issue:3 Volume:25 Page:189-199
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

van den Hurk Karin,Balint Balazs,Toomey Sinead,O’Leary Patrick C.,Unwin Louise,Sheahan Kieran,McDermott Enda W.,Murphy Ian,van den Oord Joost J.,Rafferty Mairin,FitzGerald Dara M.,Moran Julie,Cummins Robert,MacEneaney Owen,Kay Elaine W.,O’Brien Cathal P.,Finn Stephen P.,Heffron Cynthia C.B.B.,Murphy Michelle,Yela Ruben,Power Derek G.,Regan Padraic J.,McDermott Clodagh M.,O’Keeffe Allan,Orosz Zsolt,Donnellan Paul P.,Crown John P.,Hennessy Bryan T.,Gallagher William M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference49 articles.

1. Melanoma.;Miller;N Engl J Med,2006

2. From genes to drugs: targeted strategies for melanoma.;Flaherty;Nat Rev Cancer,2012

3. Vemurafenib.;Flaherty;Nat Rev Drug Discov,2011

4. . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.;Hauschild;Lancet,2012

5. Trametinib for patients with advanced melanoma.;Masuda;Lancet Oncol,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma;Virchows Archiv;2024-01-06

2. The implication of BRAF mutation in advanced colorectal cancer;Irish Journal of Medical Science (1971 -);2021-12-08

3. Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA);Calcified Tissue International;2020-11-23

4. The clinical characteristics of melanoma with BRAF V600R mutation: a case series study;Melanoma Research;2020-02

5. Transferability of Economic Evaluations of Treatments for Advanced Melanoma;PharmacoEconomics;2019-11-25